año académico: 2019-2020 estructura …...75 preguntas (45 de tipo test y 30 del tipo...

Estudios Propios 1

Estudio Propio: MÁSTER EN VISIÓN AVANZADA Y MANEJO INTEGRAL DE LA ENFERMEDAD INFLAMATORIA INTESTINAL

Código Plan de Estudios: EN78

Año Académico: 2019-2020

ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:

CURSO

Obligatorios Optativos Prácticas Externas

Memoria/ Proyecto

Créditos Créditos

Nº Asignaturas

Créditos Nº

Asignaturas Créditos Créditos

1º 52 11 8 60

2º

3º

ECTS TOTALES

52 11 8 60

PROGRAMA TEMÁTICO:

ASIGNATURAS OBLIGATORIAS

Código Asignatura

Curso Denominación Carácter OB/OP

Créditos

705444 1 ENFERMEDAD DE CROHN I OB 5

705445 1 ENFERMEDAD DE CROHN II OB 5

705446 1 COLITIS ULCEROSA I OB 4

705447 1 COLITIS ULCEROSA II OB 3

705448 1 NUTRICIÓN, ESTILO DE VIDA Y ENFERMEDAD INFLAMATORIA INTESTINAL

OB 3

705449 1 VIGILANCIA Y SEGURIDAD OB 3

705450 1 CASOS CLÍNICOS QUE ENSEÑAN OB 3

705451 1 SESIONES ICONOGRÁFICAS OB 5

705452 1 GUÍAS INTERNACIONALES SOBRE EL MANEJO DE LA ENFERMEDAD INFLAMATORIA

OB 4

705453 1 GESTIÓN INTEGRAL DE LA ENFERMEDAD INFLAMATORIA OB 4

705454 1 CÓMO PLANTEAR UN PROYECTO DE INVESTIGACIÓN EN LA ENFERMEDAD INFLAMATORIA INTESTINAL

OB 13

MEMORIA /PROYECTO

Código Asignatura

Curso Denominación Carácter OB/OP

Créditos

705455 1 TRABAJO FIN DE MÁSTER OB 8

Carácter: OB - Obligatoria; OP – Optativa

Estudios Propios 2

GUÍA DOCENTE

Año académico 2019-2020

Estudio Máster en Visión Avanzada y Manejo Integral de la Enfermedad Inflamatoria Intestinal (EN78)

Nombre de la asignatura ENFERMEDAD DE CROHN I

Carácter (Obligatoria/Optativa) Obligatoria

Créditos (1 ECTS=25 horas) 5

Modalidad (elegir una opción)

Presencial

Semipresencial

X On-line

Profesor responsable Ana Gutiérrez Casbas

Idioma en el que se imparte Español

DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor 50

Número de horas de trabajo personal del estudiante 75

Total horas 125

CONTENIDOS (Temario)

I. EPIDEMIOLOGÍA, ETIOPATOGENIA Y ANATOMÍA PATOLÓGICA: [1] LECCIÓN 1. Definición y epidemiología [2] LECCIÓN 2. Contribución de los factores genéticos y ambientales al desarrollo de la enfermedad [3] LECCIÓN 3. El Microbioma en la enfermedad de Crohn: papel en la patogénesis de la enfermedad. [4] LECCIÓN 4. Respuesta inmune adaptativa e inflamación. [5] LECCIÓN 5. Anatomía patológica. hallazgos iniciales y tardios.

II. PRESENTACIÓN CLÍNICA, HISTORIA NATURAL Y COMPLICACIONES: [6] LECCIÓN 1. Localización de la enfermedad. Formas típicas e inusuales de presentación. [7] LECCIÓN 2. Complicaciones locales: Fístulas y abscesos / Estenosis [8] LECCIÓN 3. Complicaciones y manifestaciones extraintestinales [9] LECCIÓN 4. Fisiopatología de las síntomas y signos de la enfermedad de Crohn. [10] LECCIÓN 5. Historia natural y comportamiento de la enfermedad.

III. EVALUACIÓN DIAGNÓSTICA E ÍNDICES DE ACTIVIDAD: [11] LECCIÓN 1. Datos de laboratorio. [12] LECCIÓN 2. Hallazgos endoscópicos. Sistemas para clasificar la actividad endoscópica [13] LECCIÓN 3. Diagnóstico por imagen. Sistemas para la clasificación de la actividad por técnicas de imagen [14] LECCIÓN 4. Diagnóstico diferencial [15] LECCIÓN 5. Estratificación del riesgo en la enfermedad de Crohn

Estudios Propios 3

EVALUACIÓN

75 preguntas (45 de tipo test y 30 del tipo verdadero/falso).

Se precisa responder correctamente al 70% de las cuestiones planteadas.

BIBLIOGRAFÍA

1) Satsangi J, Silverberg MS, Vermeire S, Colombel JF.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749 – 53.

2) Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis 2017; 11: 3–25

3) Gionchetti P, Dignass A , Danese S, Magro Dias FJ, Rogler G, Lakatos PL et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn's and Colitis 2017; 11: 135–49,

4) Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB (GRADE Methodologist), Sands BE. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol 2018; 113:481–517;

5) Daperno , Castiglione F , de Ridder L et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in infl ammatory bowel disease. J Crohns Colitis 2011; 5: 484 – 98.

6) Frolkis AD, Dykeman J , Negron ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies . Gastroenterology 2013; 145: 996 – 1006.

7) De Cruz P, Kamm MA , Prideaux L et al. Postoperative recurrent luminal Crohn's disease: a systematic review . Infl amm Bowel Dis 2012; 18 :758 – 77.

8) Daperno M, D'Haens G , Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD . Gastrointest Endosc 2004; 60 : 505 – 12.

9) Vande Casteele N , Herfarth H , Katz J et al. American Gastroenterological Association Institute Technical Review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases . Gastroenterology 2017; 153: 835 – 57

10) Mitrev N, Vande Casteele N, Seow CH et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in infl ammatory bowel diseases . Aliment Pharmacol Ther 2017; 46:1037 –53 .

11) Chande N, Patton PH , Tsoulis DJ et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's idsease . Cochrane Database Syst Rev 2015; 2008; (10 : CD000067) .

12) Hazlewood GS, Rezaie A, Borman M et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 201; 148: 344 – 354.e5 .

13) Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644 – 59.

14) Van Assche G, Lewis JD, Lichtenstein GR et al. Th e London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety . Am J Gastroenterol 2011; 106: 1594–602 .

15) Nguyen GC, Loft us EV Jr., Hirano I et al. American Gastroenterological Association Institute Guideline on the management of Crohn's disease after surgical resection. Gastroenterology 2017;152: 271–5.

16) Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:205-21.

17) Barreiro-de Acosta M, Marín-Jiménez I, Panadero A, Guardiola J, Cañas M, Gobbo Montoya M, Modino Y, Alcaín G, Bosca-Watts MM, Calvet X, Casellas F, Chaparro M, Fernández Salazar L, Ferreiro-Iglesias R, Ginard D, Iborra M, Manceñido N, Mañosa M, Merino O, Rivero M, Roncero O, Sempere L, Vega P, Zabana Y, Mínguez M, Nos P, Gisbert JP. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. Gastroenterol Hepatol.2018;41:118-27.

18) Domènech E, López-Sanromán A, Nos P, Vera M, Chaparro M, Esteve M, Gisbert JP, Mañosa M; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and

Estudios Propios 4

Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. Gastroenterol Hepatol 2017;40:472-83.

19) Guardiola J, Lobatón T, Cerrillo E, Ferreiro-Iglesias R, Gisbert J, Domènech E, Chaparro M, Esteve M, Rodrígues-Moranta F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol. 2018.https://doi.org/10.1016/j.gastrohep.2018.05.029

20) Gomollón F, Rubio S, Charro M, García-López S, Muñoz F, Gisbert JP, Domènech E; En Representación de GETECCU. [Reccomendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of methotrexate in inflammatory bowel disease]. Gastroenterol Hepatol 2015;38:24-30.

21) Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol. 2013;36:127-46.

Estudios Propios 5

GUÍA DOCENTE



Nombre de la asignatura ENFERMEDAD DE CROHN II




Presencial

Semipresencial

X On-line

Profesor responsable Joaquín Ernesto Hinojosa del Val





Total horas 125


I. TRATAMIENTO MÉDICO: [16] LECCIÓN 1. Objetivos globales del tratamiento. Empleo de aminosalicilatos, antibióticos y glucocorticoides. [17] LECCIÓN 2. Agentes inmunomoduladores. Tiopurínicos, Metotrexato. Tacrolimus. Talidomida [18] LECCIÓN 3. Fundamentos de las terapias biológicas. Dianas inmunológicas específicas para la enfermedad de Crohn. [19] LECCIÓN 4. Anti-factor de necrosis tumoral alfa (TNF-alfa) y antiintegrinas [20] LECCIÓN 5. Ustekinumab y agentes anti-interleukina-23 [21] LECCIÓN 6. Antagonistas Janus Kinasa (I-JAK) y otras nuevas pequeñas moléculas. [22] LECCIÓN 7. Algoritmos en el manejo de la enfermedad de Crohn. [23] LECCIÓN 8. Manejo clínico de manifestaciones y complicaciones extraintestinales

II. ASPECTOS QUIRÚRGICOS: [24] LECCIÓN 1. Indicaciones de cirugía de emergencia y electiva en la enfermedad de Crohn. [25] LECCIÓN 2. Principios generales de la cirugía en la enfermedad de Crohn [26] LECCIÓN 3. Manejo operatorio de escenarios específicos según localización [27] LECCIÓN 4. Manejo operatorio de escenarios específicos: Fístula rectovaginal o anovaginal, fístula enterovesical y enfermedad de Crohn perianal (EPA) [28] LECCIÓN 5. Prevención de la recurrencia postquirúrgica en la enfermedad de Crohn [29] LECCIÓN 6. Cuidados de rutina de la ileostomía y colostomía a corto y largo plazo. [30] LECCIÓN 7. Manejo específico de la diarrea y complicaciones asociadas al intestino corto tras la cirugía en la enfermedad de Crohn

Estudios Propios 6

EVALUACIÓN



BIBLIOGRAFÍA

1) Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O. Lindsay et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. Journal of Crohn's and Colitis, 2016; 1–23

2) F.M. Ruemmele, G. Veres, K.L. Kolho, A. Griffiths, A. Levine, J.C. Escher et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014; 8, 1179–1207

3) Fernando Magro, Paolo Gionchetti, Rami Eliakim, Sandro Ardizzone, d’Alessandro Armuzzi, Manuel Barreiro-de Acosta et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 649–67.

4) Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.

5) Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.

6) Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. Aliment Pharmacol Ther 2015;41:1055-65.

7) Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008:CD006792.

8) Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106:661-73.

9) Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. NEJM 1980; 302: 981–7.

10) Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis, Ann Int Med 1995; 123:132-42.

11) Chande N, Patton PH, Tsoulis DJ, et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2015;10:CD000067.

12) Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.

13) Fernando Gomollón, Saioa Rubio, Mara Charro, Santiago García-López, Fernando Muñoz, Javier P. Gisbert y Eugeni Domènech, en representación deGETECCU Recomendaciones del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el uso de metotrexato en la enfermedad inflamatoria intestinal. Gastroenterol Hepatol 2015;38:24-30.

14) McDonald JW, Feagan BG, Jewell D, Brynskov J, Stange EF, Macdonald JK. Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005;2:CD000297.

15) McSharry K1, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther. 2011;34:1282-94.

16) Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.

17) Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.

18) Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33;

19) Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38.

20) Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38

21) Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systemic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–59.

22) Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537-45.

Estudios Propios 7

23) Singh S, Heien HC, Sangaralingham LR, et al. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2016.;14:1120-9.

24) Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 2015;148:344-54.

25) Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015;64:1539-45.

26) Kori L Wallace, Li-Bo Zheng, Yoshitake Kanazawa, David Q Shih Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014 7; 20: 6-21

27) Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.

28) Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27.

29) Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–55.

30) Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(:1946–60.

31) Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–28.

32) Khorrami S, Ginard D, Marin-Jimenez I, et al. Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort. Inflamm Bowel Dis 2016;22:1662-9.

33) Silvio Danese, Stefanos Bonovas, Laurent Peyrin-Biroulet. Positioning Ustekinumab in Crohn’s Disease From Clinical Evidence to Clinical Practice. Journal of Crohn's and Colitis, 2017, 1–9. doi:10.1093/ecco-jcc/jjx079.

34) Silvio Danese, Ferdinando D’Amico, MD, Stefanos Bonovas, and Laurent Peyrin-Biroulet. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018. doi/10.1093/ibd/izy076/4985510.

35) William J. Sandborn, Chinyu Su, Bruce E. Sands, Geert R. D’Haens, Severine Vermeire, Stefan Schreiber et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 4;376:1723-36

36) Marcus Carbora, Vito Annese, Stephan R. Vavricka, Matthieu Allez, Manuel Barreiro-de Acosta, Kirsten Muri Boberg The First European Evidence-based Consensus on Extraintestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 239–24

37) Paolo Gionchetti, Axel Dignass, Silvio Danese, Fernando José Magro Dias, Gerhard Rogler, Péter Lakatos et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations. Journal of Crohn's and Colitis, 2016, 1–15.

38) Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011;60:930-6.

39) Eugeni Domènech, Antonio López-Sanromán, Pilar Nos, Maribel Vera, María Chaparro, María Esteve, Javier P. Gisbert y Míriam Mañosa en representación de GETECCU. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn. http://dx.doi.org/10.1016/j.gastrohep.2017.05.005.

40) Regueiro M, Schraut W, Baidoo L, et al. Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection. Gastroenterology 2009;136:441-50.

41) Regueiro M, Baidoo L, Kip KE, et al. Infliximab Maintenance Beyond One Year Prevents Postoperative Crohn's Disease Recurrence: Long-Term Follow-up From the Randomized Controlled Pilot Study. Gastroenterology 2013;144:S173-S173.

42) De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther 2015;42:867-79.

43) Julián Panés, Jordi Rimola. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy . Nature 2017; 14:652-64

44) Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease. Drugs. 2018;78:1-18. Nessar G., Fazio V.W., Tekkis P., Connor J., Wu J., Bast J et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum 2006;49:336–44.

Estudios Propios 8

GUÍA DOCENTE



Nombre de la asignatura COLITIS ULCEROSA I




Presencial

Semipresencial

X On-line

Profesor responsable Manuel Barreiro Acosta





Total horas 100


I. EPIDEMIOLOGÍA, ETIOPATOGENIA Y ANATOMÍA PATOLÓGICA. [31] LECCIÓN 1. Definición y epidemiología

[32] LECCIÓN 2. Contribución de los factores genéticos y ambientales al desarrollo de la enfermedad [33] LECCIÓN 3. Inmunopatogenia [34] LECCIÓN 5. Anatomía patológica

II. PRESENTACIÓN CLÍNICA, HISTORIA NATURAL Y COMPLICACIONES. [35] LECCIÓN 1. Formas de comienzo y presentación inicial.

[36] LECCIÓN 2. Patrones de comportamiento de la enfermedad [37] LECCIÓN 3. Complicaciones locales [38] LECCIÓN 4.: Manifestaciones extraintestinales

III. EVALUACIÓN DIAGNÓSTICA E ÍNDICES DE ACTIVIDAD. [39] LECCIÓN 1. Datos de laboratorio y hallazgos en la endoscopia. [40] LECCIÓN 2. Radiología [41] LECCIÓN 3. Índices de actividad [42] LECCIÓN 4. Diagnóstico diferencial

EVALUACIÓN



Estudios Propios 9

BIBLIOGRAFÍA

1) Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 1;11:649-670.

2) Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM, Burisch J, De Vos M, De Vries AM, Dick AD, Juillerat P, Karlsen TH, Koutroubakis I, Lakatos PL, Orchard T, Papay P, Raine T, Reinshagen M, Thaci D, Tilg H, Carbonnel F; European Crohn’s and Colitis Organisation. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:239-54.

3) Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis. 2016;10:13-9.

4) Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA, Zou GY, Feagan BG, Khanna R, Jairath V. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018 Jan 16;1:CD011450.

5) Mosli MH, Parker CE, Nelson SA, Baker KA, MacDonald JK, Zou GY, Feagan BG, Khanna R, Levesque BG, Jairath V. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017 May 25;5:CD011256.

6) Ket SN, Palmer R, Travis S. Endoscopic Disease Activity in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2015 Dec;17(12):50.

7) Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018;16:637-47.e13

8) Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol. 2017;11:317-28.

9) Garcia-Planella E, Mañosa M, Chaparro M, Beltrán B, Barreiro-de-Acosta M, Gordillo J, Ricart E, Bermejo F, García-Sánchez V, Piqueras M, Llaó J, Gisbert JP, Cabré E, Domènech E; PRECUCAL study group Investigators. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission. Scand J Gastroenterol. 2018;53:152-7.

10) Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Muñoz JE. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study. J Clin Gastroenterol. 2018;52:229-234.

11) Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:62-373.e3.

12) van der Sloot KWJ, Amini M, Peters V, Dijkstra G, Alizadeh BZ. Inflammatory Bowel Diseases: Review of Known Environmental Protective and Risk Factors Involved. Inflamm Bowel Dis. 2017;23:1499-509.

13) Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.

14) Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al; European Crohn’s and Colitis Organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.

15) Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-40.

16) Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.

17) Barreiro-de Acosta M, Magro F, Carpio D, Lago P, Echarri A, Cotter J, et al. Ulcerative colitis in northern Portugal and Galicia in Spain. Inflam Bowel Dis. 2010;16:1227-38.

18) Etchevers MJ, Aceituno M, García-Bosch O, Ordás I, Sans M, Ricart E, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009;15:1320-5.

19) Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic or unnecesary toys? Gut. 2006;55:426-31.

Estudios Propios 10

GUÍA DOCENTE



Nombre de la asignatura COLITIS ULCEROSA II




Presencial

Semipresencial

X On-line

Profesor responsable Eugeni Domènech Morral





Total horas 75


I. TRATAMIENTO MÉDICO [43] LECCIÓN 1. Objetivos globales del tratamiento. Aminosalicilatos [44] LECCIÓN 2. Glucocorticoides: sistémicos y tópicos [45] LECCIÓN 3. Inmunomoduladores: tiopurínicos, ciclosporina, metotrexato, micofenolato. [46] LECCIÓN 4: Terapias biológicas: anti-TNF alfa, Moléculas antiadhesión, Inhibidores kinasa, otros agentes biológicos. [47] LECCIÓN 5. Otros tratamientos [48] LECCIÓN 6: Algoritmos en el tratamiento de la colitis ulcerosa

II. TRATAMIENTO QUIRÚRGICO [49] LECCIÓN 1. Indicaciones de cirugía: electivas y de emergencia. [50] LECCIÓN 2. Proctocolectomía total con reservorio ileal y anastomosis ileoanal [51] LECCIÓN 3. Colectomía total con anastomosis ileorrectal. Proctocolectomía total con ileostomía, proctocolectomía total con reservorio continente de Koch, [52] LECCIÓN 4. Complicaciones del reservorio ileal: identificación y manejo

EVALUACIÓN

50 preguntas (30 de tipo test y 20 del tipo verdadero/falso). Se precisa responder correctamente al 70% de las cuestiones planteadas.

Estudios Propios 11

BIBLIOGRAFÍA

1) Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 1;11:769-84.

2) Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, Langner C, Limdi JK, Pellino G, Zagórowicz E, Raine T, Harbord M, Rieder F; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017 1;11:649-70. 3. Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol. 2018 Sep-Oct;31(5):572-582. doi: 10.20524/aog.2018.0276. Epub 2018 May 10. PubMed PMID: 30174394; PubMed Central PMCID: PMC6102462.

3) Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol. 2018 Sep 11. doi: 10.1007/s12328-018-0906-9. [Epub ahead of print] Review. PubMed PMID: 30206776.

4) 5. Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JF. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders. Clin Gastroenterol Hepatol. 2018 ;16:1374-1384. doi: 10.1016/j.cgh.2018.02.024. Epub 2018 Mar 2. Review. PubMed PMID: 29481970.

5) Núñez-Gómez L, Mesonero-Gismero F, Albillos-Martínez A, López-Sanromán A. Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease. Gastroenterol Hepatol. 2018 Jul 24. pii: S0210-5705(18)30195-X. doi: 10.1016/j.gastrohep.2018.06.010.

6) 7: Nalagatla N, Falloon K, Tran G, Borren NZ, Avalos D, Luther J, Colizzo F, Garber J, Khalili H, Melia J, Bohm M, Ananthakrishnan AN. Effect of Accelerated Infliximab Induction on Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis: A 8. 8. Retrospective Multicenter Study and Meta-Analysis. Clin Gastroenterol Hepatol. 2018 Jun 23. pii: S1542-3565(18)30641-4. doi: 10.1016/j.cgh.2018.06.031.

7) Stawowczyk E, Kawalec P. A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis. Pharmacoeconomics. 2018;36:419-34.

8) 10. De Vries LCS, Wildenberg ME, De Jonge WJ, D'Haens GR. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2017 1;11:885-93.

9) Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M; ENEIDA registry of GETECCU. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry. Am J Gastroenterol. 2018 ;113:1009-16.

10) Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D; ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa [listed at the end of the article] . Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis 2018; 25;12:687-94.

11) Bermejo F, Aguas M, Chaparro M, Domènech E, Echarri A, García-Planella E, Guerra I, Gisbert JP, López-Sanromán A; en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of thiopurines in inflammatory bowel disease. Gastroenterol Hepatol. 2018;41:205-221.

12) Gordillo J, Zabana Y, Garcia-Planella E, Mañosa M, Llaó J, Gich I, Marín L, Szafranska J, Sáinz S, Bessa X, Cabré E, Domènech E. Prevalence and risk factors or colorectal adenomas in patients with ulcerative colitis. United European Gastroenterol J 2018;6:322-30.

13) Calafat M, Lobatón T, Mañosa M, Marín L, Caballero N, Larraín M, Cabré E, Domènech E. Therapeutic requirements in active ulcerative proctitis: A single-centre study. Gastroenterol Hepatol. 2017;40:663-8.

14) Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E,

Estudios Propios 12

Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol. 2017 ;112:1709-18.

15) Domènech E, Gisbert JP. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. Gastroenterol Hepatol. 2016 Dec;39(10):677-686. doi: 10.1016/j.gastrohep.2015.11.010. Epub 2016 Mar 2. Review. English, Spanish. PubMed PMID: 26948838. 18. Llaó J, Naves JE, Ruiz-Cerulla A, Gordillo J, Mañosa M, Maisterra S, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis. 2016;48:608-12.

16) Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP,Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M,Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Jun 27. doi: 10.1038/s41395-018-0162-0. [Epub ahead of print] PubMed PMID: 29946178.

17) Whaley KG, Rosen MJ. Contemporary Medical Management of Acute SevereUlcerative Colitis. Inflamm Bowel Dis. 2018 Jun 7. doi: 10.1093/ibd/izy208. [Epub ahead of print] PubMed PMID: 2988923

18) Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze PG, Espin-Basany E, Tiret E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D'Hoore A; European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 2015;9:4-25.

19) Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis. 2014;8:1287-93. 3. Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T,4. Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017;23(:1605-13.

20) McKenna NP, Mathis KL, Pemberton JH, Lightner AL. The Impact of Age at Time ofIleal Pouch Anal Anastomosis on Short and Long-Term Outcomes in Adults. Inflamm Bowel Dis. 2018 12;24:1857-1865.

21) Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Jun 27. doi: 10.1038/s41395-018-0162-0. [Epub ahead of print] PubMed PMID: 29946178.

22) Marín-Jiménez I, Saro C, Díaz V, Acosta MB, Gómez-García M, Casbas AG. Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study). Drugs Context. 2018 Mar 6;7:212505

23) Argollo MC, Kotze PG, Spinelli A, Gomes TNF, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32-33:79-87.

24) Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol2018;32-33:71-78.

Estudios Propios 13

GUÍA DOCENTE



Nombre de la asignatura NUTRICIÓN, ESTILO DE VIDA Y ENFERMEDAD INFLAMATORIA INTESTINAL




Presencial

Semipresencial

X On-line

Profesor responsable Miguel Montoro Huguet





Total horas 75


I. CAUSAS Y CONSECUENCIAS NUTRICIONALES DE LA ENFERMEDAD INFLAMATORIA INTESTINAL [53] LECCIÓN 1. Dieta y estilo de vida como factores de riesgo de enfermedad inflamatoria intestinal [54] LECCIÓN 2. Consecuencias nutricionales de la enfermedad inflamatoria intestinal [55] LECCIÓN 3. Sistemas de evaluación nutricional en el paciente con enfermedad inflamatoria intestinal.

II. SOPORTE NUTRICIONAL EN LA EII. [56] LECCIÓN 1. Dieta como tratamiento de la enfermedad inflamatoria intestinal. [57] LECCIÓN 2. Manejo de la anemia y de la ferropenia en la EII [58] LECCIÓN 3. Reposición de micronutrientes en la EII (Vitamina D, B12, Calcio, Magnesio, Zinc, Cobre, Selenio) [59] LECCIÓN 4. Nutrición artificial en la enfermedad inflamatoria intestinal. Soporte enteral y parenteral. [60] LECCIÓN 5. Nutrición artificial en la enfermedad inflamatoria intestinal. Manejo de escenarios complejos [61] LECCIÓN 6. Recomendaciones basadas en la evidencia

EVALUACIÓN



Estudios Propios 14

BIBLIOGRAFÍA

1) Forbes A, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S et al. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. Clin Nutr 2017;36:321-47

2) Shah ND, Parian AM, Mullin GE, Limketkai BN Oral Diets and Nutrition Support for Inflammatory Bowel Disease: What Is the Evidence? Nutr Clin Pract 2015; 30:462-73

3) Limketkai BN, Wolf A, Parian AM. Nutritional Interventions in the Patient with Inflammatory Bowel Disease. Gastroenterol Clin North Am 2018;47:155-77.

4) Massironi S, Rossi RE, Cavalcoli FA, Della Valle S, Fraquelli M, Conte D. Nutritional deficiencies in inflammatory bowel disease: therapeutic approaches. Clin Nutr. 2013; 32:904-10.

5) Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008; 57: 1185-91

6) Karayiannis D, Baschali A, Sarantidou M, Alberti A, Mantzaris G, Gerasimidis K et al. Screening for nutrition risk in adults outpatients with inflammatory bowel disease: Results from a multicenter study in Greece and the United Kingdom. Clin Nutr ESPEN 2018;24:181.

7) Goh J, O´Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 307–20

8) Hansen T, Duerksen DR. Enteral Nutrition in the Management of Pediatric and Adult Crohn’s Disease. Nutrients. 201 26;10.

9) MacLellan A, Moore-Connors J, Grant S, Cahill L, Langille MGI, Van Limbergen J. The Impact of Exclusive Enteral Nutrition (EEN) on the Gut Microbiome in Crohn's Disease: A Review.Nutrients. 2017 1; 9.

10) Gong D, Yu X, Wang L, Kong L, Gong X, Dong Q.Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn's Disease via Modulation of the Gut Microbiota. Biomed Res Int. 2017; 2017:8102589.

11) Kaakoush NO, Day AS, Leach ST, Lemberg DA, Nielsen S, Mitchell HM. Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn's disease. Clin Transl Gastroenterol. 2015 15; 6:e71.

12) Kakodkar S, Mutlu EA Diet as a Therapeutic Option for Adult Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017;46(4):745-767.

13) Bischoff SC, Singer P, Koller M, Barazzoni R, Cederholm T, van Gossum A. Standard operating procedures for ESPEN guidelines and consensus papers. Clin Nutr 2015;34:1043e51.

14) Nguyen DL, Limketkai B, Medici V, Saire Mendoza M, Palmer L, Bechtold M. Nutritional Strategies in the Management of Adult Patients with Inflammatory Bowel Disease: Dietary Considerations from Active Disease to Disease Remission. Curr Gastroenterol Rep. 2016;18:55.

15) Stein J, Aksan A, Farrag K, Dignass A, Radeke HH. Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opin Pharmacother. 2017; 18:1721-37

16) Ghishan FK, Kiela PR. Vitamins and Minerals in Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017;46: 783-95

17) Rasmussen HE, Hamaker BR. Prebiotics and Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017 ;46:783-95

18) Hashash JG, Binion DG. Exercise and Inflammatory Bowel Disease: Insights into Etiopathogenesis and Modification of Clinical Course. Gastroenterol Clin North Am. 2017;46:895-905.

19) American Gastroenterological Association Technical review on tube feeding for enteral nutrition. Gastroenterology 1995; 108: 1.282-301.

20) Montoro M, Chaparro M. Problemas nutricionales específicos en las enfermedades gastrointestinales. En: Montoro M & García Pagan JC (eds). Manual de Gastroenterología y Hepatología. Grupo Editorial CTO. Madrid. 2009: 1025-75

21) Montoro M, Chaparro M. Nutrición enteral. En: Montoro M & García Pagan JC (eds). Manual de Gastroenterología y Hepatología. Grupo Editorial CTO. Madrid. 2009: 1009-24.

22) Mallon DP, Suskind DL. Nutrition in pediatric inflammatory bowel disease. Nutr Clin Pract. 2010; 25:335-9.

Estudios Propios 15

23) Lucendo A. De Rezende Cristina. Importance of nutrition in inflammatory bowel disease. World J Gastroenterol 2009; 15: 2081-28.

24) Sigall-Boneh R, Levine A, Lomer M, Wierdsma N, Allan P, Fiorino G et al. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. J Crohns Colitis. 2017 4;11:1407-19.

25) Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut. 2018; 67:1726-38.

26) Lane ER, Lee D, Suskind DL. Dietary Therapies in Pediatric Inflammatory Bowel Disease: An Evolving Inflammatory Bowel Disease Paradigm. Gastroenterol Clin North Am. 2017;46:731-44.

27) Yamamoto T. Nutrition and diet in inflammatory bowel disease. Curr Opin Gastroenterol. 2013; 29:216-21

28) Sarbagili-Shabat C, Sigall-Boneh R, Levine A. Nutritional therapy in inflammatory bowel disease. Curr Opin Gastroenterol. 2015; 31:303-8.

Estudios Propios 16

GUÍA DOCENTE



Nombre de la asignatura VIGILANCIA Y SEGURIDAD




Presencial

Semipresencial

X On-line

Profesor responsable Yamile Zabana





Total horas 75


I. RIESGOS Y COMPLICACIONES DE LAS TERAPIAS INMUNOSUPRESORAS. [62] LECCIÓN 1. Riesgos de los inmunomoduladores tiopurínicos [63] LECCIÓN 2. Riesgos de otros inmunosupresores: metotrexato, ciclosporina, tacrolimus, micofenolato.. [64] LECCIÓN 3. Efectos secundarios de las terapias biológicas [65] LECCIÓN 4. Impacto de las infecciones en pacientes en tratamiento con terapias biológicas.

II. ESTRATEGIAS DE PREVENCIÓN [66] LECCIÓN 1. Evaluación previa al tratamiento inmunosupresor y educación al paciente

[67] LECCIÓN 2. Estrategias de vacunación, quimioprofilaxis (TBC y Pneumocystis jiroveci) y tratamiento de infecciones víricas subyacentes [68] LECCIÓN 3. Listas de comprobación ("check list") previas al empleo de inmunosupresores [69] LECCIÓN 4. Fertilidad embarazo y lactancia [70] LECCIÓN 5. Programas de prevención para la prevención del cáncer.

EVALUACIÓN



Estudios Propios 17

BIBLIOGRAFÍA

1) Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis [Internet]. The Authors; 2014;8(6):443–68. Available from: http://dx.doi.org/10.1016/j.crohns.2013.12.013

2) Dave M, Purohit T, Razonable R, Loftus E V. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis [Internet]. 2014;20(1):196–212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24051931

3) Nanau RM, Cohen LB, Neuman MG. Risk of infections of biological therapies with accent on inflammatory bowel disease. J Pharm Pharm Sci. 2014;17(4):485–528.

4) Kohn A, Meddi P. How to manage IBD in patients with infections or malignancies? Dig Dis. 2012;30(4):420–4. 5) Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of

and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol. 2013;48(5):595–600.

6) Toruner M, Loftus E V., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease. Gastroenterology. 2008;134(4):929–36.

7) 7. van der Have M, Belderbos TDG, Fidder HH, Leenders M, Dijkstra G, Peters CP, et al. Screening prior to biological therapy in Crohn’s disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis [Internet]. Editrice Gastroenterologica Italiana; 2014;46(10):881–6. Available from: http://dx.doi.org/10.1016/j.dld.2014.07.006

8) Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, et al. Crohn’s Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol [Internet]. Nature Publishing Group; 2016;111(12):1806–15. Available from: http://dx.doi.org/10.1038/ajg.2016.433

9) Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006;4(5):621–30.

10) Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease. N Engl J Med. 2010;362:1383–95.

11) Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. Elsevier, Inc; 2016;14(10):1385–1397.e10.

12) Schaible TF. Long term safety of infliximab. Can J Gastroenterol. Canada; 2000 Sep;14 Suppl C:29C–32C. 13) Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis

factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. United States; 2011 Dec;306(21):2331–9.

14) Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. England; 2009 Aug;30(3):253–64.

15) Obrador A, López San Román A, Muñoz P, Fortún J, Gassull M. Guía de consenso sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Gastroenterol Hepatol. 2003;26(1):29–33.

16) Axelrad JE, Joelson A, Nobel YR, Lawlor G, Green PHR, Lichtiger S, et al. Enteric Infection in Relapse of Inflammatory Bowel Disease: The Utility of Stool Microbial PCR Testing. Inflamm Bowel Dis. United States; 2017 Jun;23(6):1034–9.

17) Zabana Y, Domènech E, López San Román A, Beltrán B, Cabriada JL, Saro C, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008;14(10):1387-91.

18) Cotter TG, Gathaiya N, Catania J, Loftus E V., Tremaine WJ, Baddour LM, et al. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol [Internet]. Elsevier Ltd; 2016; Available from: http://linkinghub.elsevier.com/retrieve/pii/S1542356516312332

19) Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340–6.

20) Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the

Estudios Propios 18

CORRONA registry. Ann Rheum Dis. England; 2010 Feb;69(2):380–6. 21) Brassard P, Bitton A, Suissa A, Sinyavskaya L, Patenaude V, Suissa S. Oral corticosteroids and the risk of

serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol [Internet]. Nature Publishing Group; 2014;109(11):1795–802. Available from: http://dx.doi.org/10.1038/ajg.2014.313

22) Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. Bmj [Internet]. 2017;j895. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.j895

23) Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet (London, England). England; 2009 Nov;374(9701):1617–25.

24) Ford AC, Peyrin-Biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol [Internet]. Nature Publishing Group; 2013;108(8):1268–76. Available from: http://dx.doi.org/10.1038/ajg.2013.138%5Cnhttp://www.nature.com/doifinder/10.1038/ajg.2013.138

25) Baddley JW, Winthrop KL, Chen L, Llu L, Grijalva CG, Delzell E, et al. Non-viral opportunistic infections in new users of TNF inhibitor therapy: results of the Safety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73(11):1942–8.

26) Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn’s disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J Crohns Colitis. England; 2013 Dec;7(11):868–77.

27) Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Saf. England; 2017 Apr;16(4):501–7.

28) Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: Results from the US VICTORY consortium. Am J Gastroenterol [Internet]. Nature Publishing Group; 2016;111(8):1147–55. Available from: http://dx.doi.org/10.1038/ajg.2016.236

29) Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. England; 2017 May;66(5):839–51.

30) Davila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa J-M, Vanaclocha F, et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. J Invest Dermatol. United States; 2017 Feb;137(2):313–21.

31) Sandborn WJ, Gasink C, Gao L-L, Blank M a, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med [Internet]. 2012;367:1519–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2307517

Estudios Propios 19

GUÍA DOCENTE



Nombre de la asignatura CASOS CLÍNICOS QUE ENSEÑAN




Presencial

Semipresencial

X On-line

Profesor responsable Miguel Mínguez Pérez





Total horas 75


I. RESOLUCIÓN DE CASOS CLÍNICOS. [71] LECCIÓN 1. Brote grave de colitis ulcerosa refractario a Glucocorticoides sistémicos. [72] LECCIÓN 2. Colitis ulcerosa que responde a granulocitoaféresis. Criterios actuales para su indicación. [73] LECCIÓN 3. Complicaciones del reservorio ileal. [74] LECCIÓN 4. Enfermedad perianal (I). Fístula simple [75] LECCIÓN 5. Enfermedad perianal (II): Fístula perianal compleja. [76] LECCIÓN 6. Cáncer de intestino delgado complicando la evolución de un paciente con enfermedad de Crohn. [77] LECCIÓN 7. Paciente con enfermedad de Crohn y espondiloartropatía refractario a anti-TNF alfa. [78] LECCIÓN 8. Enfermedad de Crohn de curso complicado tras retirada de tratamiento biológico en el 1º trimestre de la gestación. [79] LECCIÓN 9. Tuberculosis laríngeo-pulmonar en paciente tratado con terapias biológicas.

EVALUACIÓN



Estudios Propios 20

BIBLIOGRAFÍA

1) Gisbert J. Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol. 2018;32-33:59-69

2) Brain O, Travis SP. Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol. 2008 ;24:469-74

3) Acute severe ulcerative colitis: latest evidence and therapeutic implications. Dulai PS. Jairath V. Ther Adv Chronic Dis 2018; 9 65–72.

4) Bernardo S, Fernandes SR, Gonçalves AR, Valente A, Baldaia C, Santos PM. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis. 2018 Aug 6. doi: 10.1093/ibd/izy256.

5) Solina G, Mandalà S, La Barbera C, Mandalà V. Current management of intestinal bowel disease: the role of surgery. Updates Surg. 2016; 68:13-23.

6) Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018; 3:1347-52.

7) Powar MP, Martin P, Croft AR, Walsh A, Petersen D, Stevenson AR et al. Surgical outcomes in steroid refractory acute severe ulcerative colitis: the impact of rescue therapy. Colorectal Dis. 2013; 15:374-9.

8) Nelson R, Liao C, Fichera A, Rubin DT, Pekow J. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2014; 20:14-20.

9) Cabriada JL. Escenarios de idoneidad para la granulomonocitoaféresis. En Montoro M (ed). Protocolos PRODIGGEST de AEG. Visibles en www.spadiv.net

10) Pellino G, Selvaggi F Outcomes of salvage surgery for ileal pouch complications and dysfunctions. the experience of a referral centre and review of literature. J Crohns Colitis 2015;9:548-57

11) Uyeda JW, LeBedis CA, Penn DR, Murakami AM, Ramalingam V, Anderson SW et al. Ileal pouch-anal anastomosis surgery: anatomy, postoperative complications, and image-guided intervention. Semin Ultrasound CT MR. 2013;34:299-310.

12) Francone TD, Champagne B. Considerations and complications in patients undergoing ileal pouch anal anastomosis. Surg Clin North Am. 2013;93:107-43.

13) Sherman J, Greenstein AJ, Greenstein AJ. Ileal j pouch complications and surgical solutions: a review. Inflamm Bowel Dis. 2014;20:1678-85

14) Scoglio D, Ahmed Ali U, Fichera A. Surgical treatment of ulcerative colitis: ileorectal vs ileal pouch-anal anastomosis. World J Gastroenterol 2014 7;20:13211-8.

15) O'Mahoney PR, Scherl EJ, Lee SW, Milsom JW. Adenocarcinoma of the ileal pouch mucosa: case report and literature review. Int J Colorectal Dis. 2015;30:11-8.

16) Lightner AL, Wang Z, Zubair AC, Dozois EJ. A Systematic Review and Meta-analysis of Mesenchymal Stem Cell Injections for the Treatment of Perianal Crohn's Disease: Progress Made and Future Directions. Dis Colon Rectum. 2018;61:629-40

17) Grouin A, Brochard C, Siproudhis L, Leveque J, Bretagne JF, Poulain P. Perianal Crohn's disease results in fewer pregnancies but is not exacerbated by vaginal delivery. Dig Liver Dis. 2015;47:1021-6.

18) Gecse KB, Sebastian S, Hertogh Gd, Yassin NA, Kotze PG, Reinisch W, Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. J Crohns Colitis. 2016 ;10:758-65.

19) Panés J, Rimola J. Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652-64

20) Lightner AL, Faubion WA, Fletcher JG. Interdisciplinary Management of Perianal Crohn's Disease. Gastroenterol Clin North Am. 2017;46:547-562.

21) Hinojosa J. Nos P. Enfermedad perianal. En: Montoro M & García Pagán JC (eds): Manual de Práctica Clínica en Gastroenterología y Hepatología. Grupo Editorial CTO. Madrid. 2016: 447-58

22) Göttgens KW, Jeuring SF, Sturkenboom R, Romberg-Camps MJ, Oostenbrug LE, Jonkers DM Time trends in the epidemiology and outcome of perianal fistulizing Crohn's disease in a population-based cohort. Eur J Gastroenterol Hepatol. 2017;29:595-601.

23) Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A Management of perianal fistulas in Crohn's disease: an up-to-date review. World J Gastroenterol. 2015 7;21:1394-403.

24) Juncadella AC, Alame AM, Sands LR, Deshpande AR. Perianal Crohn's disease: a review. Postgrad Med. 2015; 127:266-72

25) Cahill C, Gordon PH, Petrucci A, Boutros M. Small bowel adenocarcinoma and Crohn's disease: any

http://www.spadiv.net/

Estudios Propios 21

further ahead than 50 years ago? World J Gastroenterol. 2014 7;20:11486-95 26) Malvi D, Vasuri F, Mattioli B, Gruppioni E, Fiorentino M, Gionchetti P. Adenocarcinoma in Crohn's

disease: the pathologist's experience in a tertiary referral centre of inflammatory bowel disease. Pathology. 2014;46:439-43.

27) Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004; 19: 287-93

28) Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993; 105: 1716-23

29) von Roon AC, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 2007; 50: 839-55

30) Lashner BA. Risk factors for small bowel cancer in Crohn’s disease. Dig Dis Sci 1992; 37: 1179-84 31) Grolleau C, Pote NM, Guedj NS, Zappa M, Theou-Anton N, Bouhnik Y Small bowel adenocarcinoma

complicating Crohn's disease: a single-centre experience emphasizing the importance of screening for dysplasia. Virchows Arch. 2017; 471:611-17

32) Rubio CA, Befritz R, Poppen B, Svenberg T, Slezak P. Crohn's disease and adenocarcinoma of the intestinal tract. Report of four cases. Dis Colon Rectum. 1991; 34:174-80.

33) Rashid T, Ebringer A. Gut-mediated and HLA-B27-associated arthritis: an emphasis on ankylosing spondylitis and Crohn's disease with a proposal for the use of new treatment. Discov Med. 2011 ;12:187-94

34) Liu S, Ding J, Wang M, Zhou W, Feng M, Guan W. Clinical features of Crohn disease concomitant with ankylosing spondylitis: A preliminary single-center study. Medicine (Baltimore) 2016 ;95(28):e4267.

35) Rebelo A, Leite S, Cotter J. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab. BioDrugs. 2010 14;24 Suppl 1:37-9

36) Zahiu DC, Rimbaş M, Nicolau A, Zurac S, Voiosu MR. Ankylosing spondylitis or Crohn's disease? Case report and review of the literature. Rom J Intern Med. 2010;48:347-53.

37) Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006 ;20:451-71.

38) Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 200715; 57:639-47.

39) Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000 25; 356(9244):1821-2.

40) Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis. 2004; 63:1664-9.

41) Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84.

42) Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-708

43) Seifarth C, Ritz JP, Pohlen U, Kroesen AJ, Siegmund B, Frericks B Therapy of complicated Crohn's disease during pregnancy--an interdisciplinary challenge Int J Colorectal Dis. 2014;:645-51

44) Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today. J Crohns Colitis. 2015 ;9:928-36

45) Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am. 2014;4:495-508

46) Nielsen OH, Jess T. IBD: Can TNF inhibitors be administered during the third trimester? Nat Rev Gastroenterol Hepatol. 2013; 10:130-1.

47) Simon PC, Vallano A. Anti-tumor necrosis factor-α medications and pregnancy. Med Clin (Barc). 2013 21;141:257-9.

48) Wang J, Johnson T, Sahin L, Tassinari MS, Anderson PO, Baker TE. Evaluation of the Safety of Drugs and Biological Products Used During Lactation: Workshop Summary. Clin Pharmacol Ther. 2017; 101:736-744.

49) Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench

Estudios Propios 22

to bedside. J Microbiol Immunol Infect. 2014;47:268-74 50) Ramos S, Nogueira A, Dias A, Gonçalves AF, Gaio AR, Duarte R. Tuberculosis screening in patients

receiving biological therapy. Acta Reumatol Port. 2015;40:234-40. 51) Lannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in

rheumatic patients receiving biologic therapy: international recommendations. J Rheumatol Suppl. 2014; 91:41-6.

52) Goletti D, Sanduzzi A, Delogu G Performance of the tuberculin skin test and interferon-γ release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl. 2014; 91:24-31

Estudios Propios 23

GUÍA DOCENTE



Nombre de la asignatura SESIONES ICONOGRÁFICAS




Presencial

Semipresencial

X On-line

Profesor responsable Fernando Gomollón García





Total horas 125


I. IMÁGENES PARADIGMÁTICAS: [80] LECCIÓN 1. Imágenes endoscópicas típicas de enfermedad de Crohn. [81] LECCIÓN 2. Imágenes endoscópicas típicas de colitis ulcerosa. [82] LECCIÓN 3. Enterografía por resonancia en la enfermedad de Crohn. [83] LECCIÓN 4. Megacolon tóxico. [84] LECCIÓN 5. Sacroileitis HLA-B27 en paciente con enfermedad de Crohn [85] LECCIÓN 6. Pioderma gangrenoso [86] LECCIÓN 7. Uveitis complicando la evolución de un paciente con EII. [87] LECCIÓN 8. Colangitis esclerosante primaria en paciente con colitis ulcerosa

[88] LECCIÓN 9. Osteopatía metabólica en paciente con enfermedad de Crohn. II. VIDEOENDOSCOPIA: SESIÓN DIDÁCTICA:

[89] LECCIÓN 1. Colitis ulcerosa [90] LECCIÓN 2. Enfermedad de Crohn [91] LECCIÓN 3. Cáncer complicando la evolución de la colitis ulcerosa [92] LECCIÓN 4. Dilatación neumática de estenosis fibrótica complicando la evolución de la EII.

III. ENCUENTRO CON EL PATÓLOGO: [93] LECCIÓN 1. Sobreinfección por CMV en paciente con brote grave de colitis ulcerosa corticorrefractario. [94] LECCIÓN 2. Displasia grave en biopsias del colon dirigidas por cromoendoscopia

EVALUACIÓN



Estudios Propios 24

BIBLIOGRAFÍA

1) Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J. European Crohn's and Colitis Organisation (ECCO): European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018

2) Gerson LB. Use and misuse of small bowel video capsule endoscopy in clinical practice. Clin Gastroenterol Hepatol. 2013 ;11:1224-3

3) Vucelic B. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Dig Dis. 2009; 27:269-77.

4) Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY et al. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 8;(8):CD010642.

5) Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16:2131-6

6) Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A et al. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.Gastroenterology. 2013; 145:978-86

7) Mohammed Vashist N, Samaan M, Mosli MH, Parker CE, MacDonald JK, Nelson SA et al. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018 Jan 16; 1:CD011450.

8) Jesuratnam-Nielsen K, Løgager VB, Rezanavaz-Gheshlagh B, Munkholm P, Thomsen HS.Plain magnetic resonance imaging as an alternative in evaluating inflammation and bowel damage in inflammatory bowel disease--a prospective comparison with conventional magnetic resonance follow-through. Scand J Gastroenterol. 2015 ;50:519-27

9) Schunk K. Small bowel magnetic resonance imaging for inflammatory bowel disease.Top Magn Reson Imaging. 2002;13:409-25.

10) Jesuratnam-Nielsen K, Løgager VB, Munkholm P, Thomsen HS.Diagnostic accuracy of three different MRI protocols in patients with inflammatory bowel disease.Acta Radiol Open. 2015; 4:2058460115588099I.

11) Park SH, Huh J, Park SH, Lee SS, Kim AY, Yang SK Diffusion-weighted MR enterography for evaluating Crohn's disease: Effect of anti-peristaltic agent on the diagnosis of bowel inflammation.Eur Radiol. 2017; 27:2554-62.

12) Choi SH, Kim KW, Lee JY, Kim KJ, Park SH. Diffusion-weighted Magnetic Resonance Enterography for Evaluating Bowel Inflammation in Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2016; 22:669-79.

13) Qiu Y, Mao R, Chen BL, Li XH, He Y, Zeng ZR, Li ZP, Chen MH. Systematic review with meta-analysis: magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn's disease. Aliment Pharmacol Ther. 2014; 40:134-46.

14) Woodhouse E. Toxic Megacolon: A Review for Emergency Department Clinicians. J Emerg Nurs. 2016; 42:481-6

15) van Geenen EJ, Sachar DB. Infliximab in Crohn's disease-associated toxic megacolon.J Clin Gastroenterol. 2012 ;46:321-3.

16) Leifeld L, Kruis W. Current management of toxic megacolon. Z Gastroenterol. 2012;50:316-22 17) Koch A, Tacke F, Streetz KL, Trautwein C. Treatment of inflammatory bowel disease in intensive care

medicine. Dtsch Med Wochenschr. 2012; 137:1107-18; 18) Leclerc-Jacob S, Lux G, Rat AC, Laurent V, Blum A, Chary-Valckenaere I et al. The prevalence of inflammatory

sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients. Aliment Pharmacol Ther 2014;39:957-62.

19) Fries W, Giofré MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97:499-500

20) Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn's disease. Aliment Pharmacol Ther. 2009 ;29:193-7

21) Del Grande F, Carrino JA, Zanetti M. Magnetic resonance imaging of spondyloarthritis: spine and SI joints. Top Magn Reson Imaging. 2011;22:83-8.

22) Aydingoz U, Yildiz AE, Ozdemir ZM, Yildirim SA, Erkus F, Ergen FB. A critical overview of the imaging arm of the ASAS criteria for diagnosing axial spondyloarthritis: what the radiologist should know. Diagn Interv Radiol. 2012; 18:555-65

23) Cozzani E, Gasparini G, Parodi A. Pyoderma gangrenosum: a systematic review. G Ital Dermatol Venereol. 2014 ;149. 587-600

24) Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M et al.

Estudios Propios 25

Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013 ;58:2949-54

25) Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007; 215:245-51.

26) Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982-92

27) Cloché V, Buisson A, Tréchot F, Batta B, Locatelli A, Favel C et al. Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease. Dig Liver Dis. 2013;45:195-9

28) Yilmaz S, Aydemir E, Maden A, Unsal B.The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis. 2007; 22:1027-30

29) Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:135-9.

30) Paroli MP, Spinucci G, Bruscolini A, La Cava M, Abicca I. Uveitis preceding Crohn's disease by 8 years. Int Ophthalmol. 2011;31:413-5

31) Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013 9;382(9904):1587-99

32) Lazaridis KN, LaRusso NF. Primary Sclerosing Cholangitis. N Engl J Med. 2016 22; 375:1161-70 33) Block M, Jørgensen KK, Oresland T, Lindholm E, Grzyb K, Cvancarova M et al. Colectomy for patients with

ulcerative colitis and primary sclerosing cholangitis - what next. J Crohns Colitis. 2014;8:421-30 34) Duca I, Ramírez de la Piscina P, Estrada S, Calderón R, Spicakova K, Urtasun L et al. Steroid-refractory

ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. World J Gastroenterol. 2013 28;19:590-3

35) Chaparro M, Trapero-Marugán M, Guijarro M, López C, Moreno-Otero R, Gisbert JP. Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohns Colitis. 2013;7(2):e61-5

36) Wohl P, Hucl T, Drastich P, Kamenar D, Spicak J, Honsova E et al. Epithelial markers of colorectal carcinogenesis in ulcerative colitis and primary sclerosing cholangitis. World J Gastroenterol. 2013;19:2234-41.

37) Duca I, Ramírez de la Piscina P, Estrada S, Calderón R, Spicakova K, Urtasun L et al. Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab. World J Gastroenterol. 2013 28;19:590-3

38) Krajcovicova A, Kuzma M, Hlavaty T, Hans D, Koller T, Jackuliak P et al. Decrease of trabecular bone score reflects severity of Crohn's disease: results of a case-control study. Eur J Gastroenterol Hepatol. 2018;30:101-6

39) von Scheven E, Corbin KJ, Stagi S, Cimaz R. Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep 2014;12:289-99

40) Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr. 2006;43:42-51.

41) Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005;11:1108-18.

42) Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2003;5:225-32

43) Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 2014 10;345:235-41. 44) Yashiro M. Ulcerative colitis-associated colorectal cancer. World J Gastroenterol. 2014 28;20:16389-97 45) Scarpa M, Castagliuolo I, Castoro C, Pozza A, Scarpa M, Kotsafti A et al. Inflammatory colonic carcinogenesis:

a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis. World J Gastroenterol. 2014 14;20:6774-85

46) Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000; 47:57-70

47) Herszenyi L, Miheller P, Tulassay Z. Carcinogenesis in inflammatory bowel disease. Dig Dis. 2007;25:267-9. 48) Hassan C, Zullo A, De Francesco V, Ierardi E, Giustini M, Pitidis A et al. Systematic review: Endoscopic

dilatation in Crohn's disease. Aliment Pharmacol Ther. 2007;26:1457-6 49) Morini S, Hassan C, Lorenzetti R, Zullo A, Cerro P, Winn S Long-term outcome of endoscopic pneumatic

dilatation in Crohn's disease. Dig Liver Dis. 2003;35:893-7. 50) Singh A, Agrawal N, Kurada S, Lopez R, Kessler H, Philpott J et al. Efficacy, Safety, and Long-term Outcome of

Serial Endoscopic Balloon Dilation for Upper Gastrointestinal Crohn's Disease-associated Strictures-A Cohort Study. J Crohns Colitis 2017 1;11:1044-51.

Estudios Propios 26

51) Keuchel M. Double balloon (push-and-pull) enteroscopy: breakthrough in the management of small intestinal strictures in Crohn's disease? Eur J Gastroenterol Hepatol. 2007;19:523-5.

52) Erkelens GW, van Deventer SJ. Endoscopic treatment of strictures in Crohn's disease. Best Pract Res Clin Gastroenterol. 2004;18:201-7.

53) Maconi G, Colombo E, Zerbi P, Sampietro GM, Fociani P, Bosani M Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis. 2005; 37:418-23

54) Tárraga Rodríguez I, Ferreras Fernández P, Vicente Gutiérrez M, de Arriba JJ, García Mouriño ML.Ulcerative colitis and cytomegalovirus infection. An Med Interna. 2003;20:85-7.

55) Kim YS, Kim YH, Kim JS, Jeong SY, Park SJ, Cheon JH et al. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver. 2014;8:643-7

56) Freire P, Figueiredo P, Cardoso R, Donato MM, Ferreira M, Mendes S et al. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial. Inflamm Bowel Dis. 2014;20:2038-45.

57) Konijeti GG, Shrime MG, Ananthakrishnan AN, Chan AT.Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointest Endosc. 201;79:455-65

Estudios Propios 27

GUÍA DOCENTE



Nombre de la asignatura GUÍAS INTERNACIONALES SOBRE EL MANEJO DE LA ENFERMEDAD INFLAMATORIA




Presencial

Semipresencial

X On-line

Profesor responsable Javier Pérez Gisbert





Total horas 100


I. GUÍAS DE LA WGO Y OTROS ORGANISMOS MULTINACIONALES [95] LECCIÓN 1. World Gastroenterology Organisation (WGO): Global guidelines on inflammatory bowel disease, update (2015) J Clin Gastroenterol 2016;50:803-18. [96] LECCIÓN 2. R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639-51 [97] LECCIÓN 3. WGO, International Organisation for Inflammatory Bowel Disease (IOIBD), European Society of Coloproctology (ESCP) and Robarts Clinical Trials: A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 2014;63:1381-92.

II. GUÍAS de EE.UU [98] LECCIÓN 1. American College of Gastroenterology (ACG): Clinical guideline for preventive care in

inflammatory bowel disease (2017) [99] LECCIÓN 2. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease (2017) [100] LECCIÓN 3. Management Strategies to Improve Outcomes of Patients with Inflammatory Bowel Diseases (2017) [101] LECCIÓN 4. American Society of Colon and Rectal Surgeons (ASCRS): Clinical practice guideline for the surgical management of Crohn's disease (2015) [102] LECCIÓN 5. American Society for Gastrointestinal Endoscopy (ASGE): Guideline on the role of endoscopy in inflammatory bowel disease (2015) [103] LECCIÓN 6. Crohn's and Colitis Foundation of America (CCFA): Guidelines for imaging of Crohn's perianal fistulizing disease (2015) [104] LECCIÓN 7. CCFA: Guidelines for the surgical treatment of perianal fistulizing disease (2015) [105] LECCIÓN 8. (AGA) Guideline on the use of thiopurines, methotrexate, and anti–TNF-alpha for

Estudios Propios 28

the induction and maintenance of remission in Crohn's disease (2013) III. GUÍAS EUROPEAS. ECCO

[106] LECCIÓN 1. 2nd N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis (2018) [107] LECCIÓN 2 ECCO-ESCP Consensus on Surgery for Crohn's Disease (2018) [108] LECCIÓN 3. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations… (2017) [109] LECCIÓN 4 Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. (2017) [110] LECCIÓN 5 Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO] (2017) [111] LECCIÓN 6 European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly (2017) [112] LECCIÓN 7. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. [113] LECCIÓN 8 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. [114] LECCIÓN 9 European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease (2016) [115] LECCIÓN 10 The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease (2016) [116] LECCIÓN 11. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease (2014) [117] LECCIÓN 12. European evidence based consensus on surgery for ulcerative colitis (2015) [118] LECCIÓN 13. European Crohn's and Colitis Organisation (ECCO): European evidence based consensus for endoscopy in inflammatory bowel disease (2013)

EVALUACIÓN


BIBLIOGRAFÍA

GUÍAS DE LA WGO Y OTROS ORGANISMOS MULTINACIONALES 1) Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL World Gastroenterology Organisation (WGO):

Global guidelines on inflammatory bowel disease, update (2015) J Clin Gastroenterol 2016;50:803-18. 2) Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus

statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology. 2015;148:639-51

3) Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC6 WGO, International Organisation for Inflammatory Bowel Disease (IOIBD), European Society of Coloproctology (ESCP) and Robarts Clinical Trials: A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut 2014;63:1381-92.

GUÍAS de EE.UU 4) Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. American College of Gastroenterology (ACG): Clinical

guideline for preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017 ;112:241-58. 5) Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American Gastroenterological Association

Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153:827-34.

6) Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients with Inflammatory Bowel Diseases. Gastroenterology. 2017;152:351-61

7) Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB et al. American Society of Colon and Rectal Surgeons (ASCRS): Clinical practice guideline for the surgical management of Crohn's disease. Dis Colon Rectum. 201;58:1021-36

8) American Society for Gastrointestinal Endoscopy (ASGE). Standards of Practice Committee, Shergill AK,

Estudios Propios 29

Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V et al. : Guideline on the role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101-21

9) Ong EM, Ghazi LJ, Schwartz DA, Mortelé KJ. Crohn's and Colitis Foundation of America (CCFA): Guidelines for imaging of Crohn's perianal fistulizing disease.Inflamm Bowel Dis. 2015;21:731-6.

10) Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA; Society of Abdominal Radiology Crohn’s Disease-Focused Panel. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease Gastroenterology. 2018;154:1172-94.

11) CCFA: Guidelines for the surgical treatment of perianal fistulizing disease. 12) Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; (AGA) Guideline on the use of thiopurines,

methotrexate, and anti–TNF-alpha for the induction and maintenance of remission in Crohn's disease. Gastroenterology. 2013;145:1459-63

GUÍAS EUROPEAS. ECCO 13) O'Connor M, Bager P, Duncan J, Gaarenstroom J, Younge L, Détré P et al. 2nd N-ECCO Consensus Statements

on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis.J Crohns Colitis. 2013;7:744-64

14) Kemp K, Dibley L, Chauhan U, Greveson K, Jäghult S, Ashton et al. Second N-ECCO Consensus Statements on the European Nursing Roles in Caring for Patients with Crohn's Disease or Ulcerative Colitis. J Crohns Colitis. 2018 28;12:760-76

15) Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G et al. ECCO-ESCP Consensus on Surgery for Crohn's Disease. J Crohn´s Colitis. 2018 5;12:1-1

16) Magro F, Gionchetti P2, Eliakim R3, Ardizzone S4, Armuzzi A5, Barreiro-de Acosta M. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations. J Crohns Colitis. 2017 1;11:649-70.

17) Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 1;11:769-78.

18) Sigall-Boneh R, Levine A, Lomer M, Wierdsma N, Allan P, Fiorino G et al. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO]. J Crohns Colitis. 2017 4;11:1407-19.

19) Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N et al. European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly. J Crohns Colitis. 2017 1;11:263-273

20) Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay J et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis 2017;11:3-25

21) Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos P et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017;11:135-49

22) Rieder F, Latella G, Magro F, Yuksel ES, Higgins PD, Di Sabatino A et al. European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease. J Crohns Colitis 2016 ;10:873-85

23) Harbord M, Annese V, Vavricka SR, Allez M, Barreiro-de Acosta M, Boberg KM et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016 ;10:239-5

24) Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207.

25) Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M et al. European evidence based consensus on surgery for ulcerative colitis. J Crohns Colitis. 201; 9:4-25.

26) Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J. European Crohn's and Colitis Organisation (ECCO): European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018

27) Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827-51

28) Feakins RM. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. British Society of Gastroenterology. J Clin Pathol. 2013; 66:1005-26

Estudios Propios 30

GUÍA DOCENTE



Nombre de la asignatura GESTIÓN INTEGRAL DE LA ENFERMEDAD INFLAMATORIA




Presencial

Semipresencial

X On-line

Profesor responsable Pilar Nos Mateu





Total horas 100


I. CALIDAD DE VIDA. FUENTES DE INFORMACIÓN FIDEDIGNAS PARA PACIENTES [119] LECCIÓN 1. Impacto de la enfermedad inflamatoria intestinal sobre la calidad de vida relacionada con la salud (CVRS). Indicadores e instrumentos de medida. [120] LECCIÓN 2. Cuestiones frecuentemente planteadas por los pacientes [121] LECCIÓN 3. Educación al paciente / Fuentes de información

II. DECISIONES COMPARTIDAS (“SHARED DECISION MAKING”) CLÍNICO-PACIENTE. [122] LECCIÓN 1. Actores que intervienen en la toma de decisiones compartidas [123] LECCIÓN 2. Estándares de calidad de la “International Patient Decision AIDS Collaboration de Canadá (IPDAS)” [124] LECCIÓN 3. Gestión de decisiones compartidas en el National Health Service (NHS) [125] LECCIÓN 4. Ejemplos de aproximación a puntos de decisión sobre temas controvertidos de la Clínica Mayo [http://shareddecisions.mayoclinic.org] [126] LECCIÓN 5. Ejemplos de decisiones compartidas en el ámbito de la enfermedad inflamatoria intestinal: pruebas diagnósticas, intervenciones, tratamientos….

III. INDICADORES Y ESTÁNDARES DE CALIDAD. [127] LECCIÓN 1. Razones para la acreditación de Unidades de Enfermedad inflamatoria intestinal

[128] LECCIÓN 2. Indicadores de estructura [129] LECCIÓN 3. Indicadores de proceso [130] LECCIÓN 4. Indicadores de resultados

Estudios Propios 31

EVALUACIÓN


BIBLIOGRAFÍA

1) Alrubaiy L, Rikaby I, Dodds P, Hutchings HA, Williams JG. Systematic review of health-related quality of life measures for inflammatory bowel disease. J Crohns Colitis 2015;9:284-92

2) Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut 2014;63:1092–102.

3) Hoivik ML, Bernklev T, Solberg IC, et al. Patients with Crohn’s disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study. J Crohns Colitis. 2012;6:441–453.

4) Hoivik ML, Moum B, Solberg IC, et al. Health-related quality of life in patients with ulcerative colitis after a 10-year disease course: results from the IBSEN study. Inflamm Bowel Dis. 2012;18: 1540–9.

5) Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis. 2007;1:10–20.

6) Karwowski CA, Keljo D, Szigethy E Strategies to improve quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15:1755-64.

7) Blagden S, Kingstone T, Soundy A, Lee R, Singh S, Roberts L. A Comparative Study of Quality of Life in Persons With Irritable Bowel Syndrome and Inflammatory Bowel Disease. Gastroenterol Nurs. 2015;38:268-78

8) A to Z Inventory - Patient Decision Aids - Ottawa Health Research Institute [Internet]. [cited 2012 Apr 3]; Available from: http://decisionaid.ohri.ca/

9) Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut 2012;61:459-65

10) Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther. 2008; 27 Suppl 1:1-8.

11) Baars JE, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion. 2010; 81:113-9.

12) Westwood N, Travis SP. Review article: what do patients with inflammatory bowel disease want for their clinical management?. Aliment Pharmacol Ther. 2008 Mar;27 Suppl 1:1-8

13) Clarke K, Bilal M, Abdul-Baki H, Lebovitz P, El-Hachem S. College inflammatory bowel disease (C-IBD) day: a targeted approach to shared decision-making in college age students with IBD-a 2-year pilot project. Int J Colorectal Dis. 2017;32:1019-23

14) Veilleux S, Noiseux I, Lachapelle N, Kohen R, Vachon L, Guay BW5. Patients' perception of their involvement in shared treatment decision making: Key factors in the treatment of inflammatory bowel disease. Send to

15) Patient Educ Couns. 2018;101:331-9. 16) Gionfriddo MR, Leppin AL, Brito JP, Leblanc A, Boehmer KR, Morris MA et al. A systematic review of shared

decision making interventions in chronic conditions: a review protocol. Syst Rev. 2014 15;3:38. 17) Barry MJ, Edgman-Levitan S. Shared decision making–pinnacle of patient-centered care. New Engl J Med.

2012;366:780–1. 18) Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Shared Decision Making: A Model

for Clinical Practice. J Gen Intern Med 27:1361–7 19) Coulter A. Do patients want a choice and does it work? BMJ. 2010;341:973–5 20) Thistlethwaite J, Evans R, Tie RN, Heal C. Shared decision making and decision aids - a literature review. Aust

Fam Physician. 2006;35:537-40. 21) Epstein RM, Alper BS, Quill TE. Communicating Evidence for Participatory Decision Making. JAMA.

2004;291:2359–66 22) Levinson W, Lesser CS, Epstein RM. Developing physician communication skills for patient-centered care.

Health affairs (Project Hope). 2010;29:1310–8 23) Braddock CH, Fihn SD, Levinson W, Jonsen AR, Pearlman RA. How doctors and patients discuss routine

clinical decisions: informed decision making in the outpatient setting. 1997;12:339–45. 24) Stacey D, Bennett C, Barry M, Col N, Eden K, Holmes-Rovner, M Llewellyn-Thomas, H Lyddiatt A, et al.

Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews. 2011;as well as(10):CD001431

25) Say R, Murtagh M, Thomson R. Patients’ preference for involvement in medical decision making: a narrative review. Patient Educ Counsel. 2006;60:102.

http://decisionaid.ohri.ca/

Estudios Propios 32

26) Epstein RM, Peters E. Beyond information: exploring patients’ preferences. JAMA. 2009;302(2):195–7. 27) Elwyn G, Miron-Shatz T. Deliberation before determination: the definition and evaluation of good decision

making. Health Expectations. 2009;13:139–47 28) Legare F, Turcotte S, Stacey D, Ratte S, Kryworuchko J, Graham ID: Patients’ perceptions of sharing in

decisions: a systematic review of interventions to enhance shared decision making in routine clinical practice. Patient 2012, 5:1–19

29) Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP, de Jong CA: Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom 2008, 77:219–26.

30) Legare F, Politi MC, Drolet R, Desroches S, Stacey D, Bekker H: Training health professionals in shared decision-making: an international environmental scan. Patient Educ Couns 2012, 88:159–69.

31) Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M et al. Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis. 2014;8:240-51.

32) Quality indicators for inflammatory bowel disease: development of process and outcome measures. 33) Melmed GY, Siegel CA, Spiegel BM, Allen JI, Cima R, Colombel JF et al. Inflamm Bowel Dis. 2013; 19:662-8. 34) Morar PS, Hollingshead J, Bemelman W, Sevdalis N, Pinkney T, Wilson G et al. Quality indicators for

inflammatory bowel disease: development of process and outcome measures. J Crohns Colitis. 2014 Mar:240-51

35) Bitton A, Vutcovici M, Lytvyak E, Kachan N, Bressler B, Jones J et al. Selection of Quality Indicators in IBD: Integrating Physician and Patient Perspectives. Inflamm Bowel Dis. 2018 Aug 29 doi: 10.1093/ibd/izy259.

Estudios Propios 33

GUÍA DOCENTE



Nombre de la asignatura CÓMO PLANTEAR UN PROYECTO DE INVESTIGACIÓN EN LA ENFERMEDAD INFLAMATORIA INTESTINAL




Presencial

Semipresencial

X On-line

Profesor responsable Fernando Fernández Bañares





Total horas 325


I. ¿PORQUÉ INVESTIGAR EN EL MEDIO HOSPITALARIO? II. BIOESTADÍSTICA

[132] LECCIÓN 1. Bioestadística I [133] LECCIÓN 2. Bioestadística II [134] LECCIÓN 3. Bioestadística III

III. EPIDEMIOLOGÍA [135] LECCIÓN 1. Epidemiología I [136] LECCIÓN 2. Epidemiología II [137] LECCIÓN 3. Epidemiología III [138] LECCIÓN 4. Epidemiología IV [139] LECCIÓN 5. Epidemiología V [140] LECCIÓN 6. Epidemiología VI [141] LECCIÓN 7. Epidemiología VII

IV. LECTURA CRÍTICA, REVISIONES SISTEMÁTICAS, GESTOR DE REFERENCIAS Y BASES DE DATOS. [142] LECCIÓN 1. Revisiones sistemáticas. Instalación y tutorial de uso del gestor de referencias Mendeley.

Revisión de tutorial online de PubMed [142] LECCIÓN 2. Analizar una base de datos y escribir una research letter [143] LECCIÓN 3. Lectura crítica de un artículo científico. ¿Qué se espera de un revisor?

V. MEDICINA TRASLACCIONAL, ASPECTOS ÉTICO-LEGALES DE LA INVESTIGACIÓN-COMUNICACIÓN. [145] LECCIÓN 1. Investigación biomédica traslacional [146] LECCIÓN 2. Aspectos éticos de la investigación clínica [147] LECCIÓN 3. Normas de buena práctica y aspectos legales de la investigación biomédica [148] LECCIÓN 4. Habilidades de comunicación: Comunicar resultados en Reuniones y Congresos

Estudios Propios 34

EVALUACIÓN


BIBLIOGRAFÍA

1) Martínez MA, Sánchez-Villegas A, Toledo EA, Faulín J. Bioestadística amigable. 3ª edición. Barcelona: Elsevier, 2014. 707 p.

2) Glantz SA. Bioestadística. 6ª edición. México: McGraw Hill, 2005. 520 p. 3) Causal inference (inferencia causal): https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/

a. Part I, Chapters 1-10 (updated 26 August 2018) b. Part II, Chapters 11-17 (updated 11 February 2018) c. Part III, Chapters 19-20 (updated 19 May 2017) d. References e. NHEFS data, in SAS, Stata, and MS Excel formats f. Codebook for NHEFS data g. SAS programs for Part II h. STATA programs for Part II, by Israel Agaku, Ehsan Karim, Jay Kaufman, and Eleanor Murray i. R programs for Part II, by Justin Bohn, Susan Gruber, Ehsan Karim, and Robert Platt j. Python programs for Part II, by James Fiedler

4) Montoro M. Principios esenciales de la Práctica Clínica. En Montoro M & García Pagán JC (eds). Manual de Práctica Clínica en Gastroenterología y Hepatología. Grupo Editorial CTO. Madrid. Copyright 2016: 1-20

5) Acerca de la buena comunicación y Medicina: https://www.intramed.net/sitios/librovirtual6/capitulos.htm 6) Comunicación Clínica. Principios y habilidades para la práctica. Roger Ruiz Moral. Panamericana, 2014. 7) La Comunicación con el Paciente. Arturo Merayo Pérez, Esteban Bravo Pérez, Fernando Gordón Carbonell.

Elsevier, 2014. 8) Principios de ética biomédica. TOM L. BEAUCHAMP. Editorial Masson. 1998. 548 pág. 9) ¿Qué hace que la investigación clínica sea ética?: Ezekiel Emanuel

http://www.bioetica.edu.uy/actividades/cbcc6/requisitos_eticos_para_la_investigacion.pdf 10) Ética e investigación biomédica. Fernando Sánchez Torres.

https://dialnet.unirioja.es/descarga/articulo/3989479.pdf. 11) Instituto de Salud Carlos III: http://www.isciii.es/ISCIII/es/general/index.shtml 12) Declaración de Helsinki: principios éticos para la investigación médica sobre sujetos humanos.

https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/ 13) Pautas éticas internacionales para la investigación biomédica en seres humanos (CIOMS, 2016).:

http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-evaluacion/fd-evaluacion-etica-investigacion/pdf_2017/CIOMS-2016-Ethical-Guidelines-for-Health-related-Research-Involving-Humans.pdf

14) Ley 41/2002, de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica. Texto consolidado: http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-evaluacion/fd-evaluacion-etica-investigacion/pdf_2015/Ley_41-2002_autonomia_del_paciente_texto_consolidado.pdf

15) Ley de investigación biomédica. http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/Ley_Investigacion_Biomedica.pdf

https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/

https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/



http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/Ley_Investigacion_Biomedica.pdf

Estudios Propios 35

GUÍA DOCENTE



Nombre de la asignatura TRABAJO FIN DE MÁSTER




Presencial

Semipresencial

X On-line

Profesor responsable Miguel Montoro Huguet* *En representación de un equipo de tutores y evaluadores.





Total horas 200


El alumno trabajará y será evaluado en los siguientes aspectos: I. CALIDAD DE LAS FUENTES BIBLIOGRÁFICAS CONSULTADAS. II. REVISIÓN DEL ESTADO ACTUAL DEL TEMA OBJETO DEL PROYECTO. III. CALIDAD DE LA HIPÓTESIS PLANTEADA PARA EL PROYECTO. IV. CALIDAD DE LOS OBJETIVOS PRINCIPAL Y SECUNDARIOS V. CALIDAD DEL DISEÑO. TIPO DE ESTUDIO, POBLACIÓN DIANA. CRITERIOS DE INCLUSIÓN Y

EXCLUSIÓN Y DEFINICIÓN DE LAS VARIABLES. VI. CONSIDERACIONES ÉTICAS AL PROYECTO. VII. ORIGINALIDAD DEL PROYECTO VIII. IDONEIDAD Y ADECUACIÓN DEL PROYECTO A LA HIPÓTESIS Y OBJETIVOS PLANTEADOS.

EVALUACIÓN

Personalizada por alumno en función de los epígrafes anteriores y un baremo preestablecido (Puntuación de 1-10).

Nota exigida para obtener una evaluación favorable: 7 puntos.

año académico: 2019-2020 estructura …...75 preguntas (45 de tipo test y 30 del tipo...

Documents